- Open Access
The stability of osseous metastases of the spine in lung cancer – a retrospective analysis of 338 cases
© Rief et al.; licensee BioMed Central Ltd. 2013
- Received: 3 April 2013
- Accepted: 11 August 2013
- Published: 13 August 2013
The objective of this retrospective analysis is to systematically assess osseous lesions on the basis of a validated scoring system in terms of stability and fractures prior to and following radiotherapy in 338 lung cancer patients with bone metastases in the vertebral column.
The stability of 338 patients with 981 osteolytic metastases in the thoracic and lumbar spine was evaluated retrospectively on the basis of the Taneichi-Score between January 2000 and January 2012.
64% (215 patients) were classified stable prior to radiotherapy. Of the stable osseous metastases, none were rated unstable in the further course (p < 0.001, McNemar test). Of the 123 patients in whom the metastases were classified unstable prior to radiotherapy, 21 patients (17%) were classified stable after three months, and 30 patients (24%) stable after six months. A pathological fracture was diagnosed in 62 patients (18%) prior to radiotherapy. Regarding cases of osteolytic metastases of the vertebral bodies in which no fractures could be detected prior to the start of therapy, fractures occurred in 2% of all patients (n = 7) within six months following radiotherapy.
Our analysis demonstrated that pathological fractures following radiotherapy occur in the very minority of vertebral lesions for patients with a favorable outcome. The use of a systematic radiological scoring system to classify osteolytic metastases of the vertebral column has shown to be feasible in daily routine. Prospective clinical trials are warranted in order to analyse, to what extent patients with osseous metastases can be mobilized by physiotherapy for strengthening the paravertebral muscles before radiotherapy effects can be measured by means of radiological recalcification.
- Bone metastases
- Lung cancer
Metastases of the bone occur in 30-36% of the patients with lung cancer; 65% of these metastases are discovered at the time of the initial staging[1, 2]. The vertebral column is the principal localization of the osseous metastases and is in many cases an indication of an advanced stage of a malignant primary disease[3, 4].
Advanced lung cancer is diagnosed in over two thirds of the patients, a figure that correlates with a high mortality. In the majority of patients in lung cancer with bone metastases, the treatment of osteolytic metastases in the daily clinical practice is common. The aim of therapy here is to reduce pain, to improve the functionality, and to prevent complications, for example compression of the spinal cord and pathological fractures. The treatment of osseous metastases is complex and requires a multidisciplinary approach in the form of analgesic therapy, systemic treatment, radiotherapy, and surgical interventions as measures to optimize the prospects of success in the individual therapy of patients. Metastases of the bone play a major role in everyday clinical practice, capable of causing distinct symptoms of pain, bone fractures, compression of the spinal cord, and hypercalcaemia, with a significant reduction in the patients’ quality of life. Metastases occur most frequently as osteolytic factors in connection with bronchial carcinoma and have significant effects on the stability of the vertebral column and the patients’ mobility.
Palliative radiotherapy represents one of the principal therapeutical methods for patients with osseous metastases. The most frequent indications for therapy are the presence of pain, existing or impending instability, neurological symptoms due to compression of the spinal cord, or following surgical intervention. An essential aspect is the stability of the vertebral bodies affected. Patients with unstable osteolytic vertebral bodies are usually given an orthopedic thoracic corset to wear. The pain that is already present is hence additionally compounded by an impairment of mobility and subsequently a further reduction in the patients’ quality of life.
The German Association for Sports Medicine and Prevention and the German Cancer Society have published guidelines for the design of training and sports programs for tumor patients; in these guidelines, the targeted sports intervention is deemed contraindicated in patients with osseous metastases. A systematic classification regarding the stability of the metastases in the vertebral bodies has so far been carried out in only relatively few clinics. The use of a validated scoring system to assess the stability of osseous metastases in the vertebral column may produce early mobilization in palliative-stage patients. The objective of this retrospective analysis is to systematically assess the osseous lesions in terms of stability and fractures prior to and following radiotherapy in bronchial-carcinoma patients with bone metastases.
Of a total population of 963 patients whose osseous lesions were treated by radiotherapy at the University Clinic of Heidelberg for osteolytic metastases of the vertebral column due to histologically diagnosed bronchial carcinoma in the period from January 2000 up to January 2012, 338 patients exhibited a survival time exceeding six months; these were examined using computer tomography. This group of patients was screened in this retrospective analysis. Inclusion criteria for the further investigation were radiotherapy performed in the segments afflicted, osteolytic metastases, localization in the thoracic and lumbar spine, and a minimum duration of follow-up treatment of six months. Accordingly 338 patients presenting 981 osseous lesions in the thoracic and lumbar spine were evaluated. Many patients exhibited more than one treated lesion; only one lesion per vertebral body was included in the analysis. The patient data were taken from the Heidelberg NCT Cancer Register. This study was given the positive vote of approval of the Heidelberg Ethics Committee on 22 October 2012.
Squamous cell carcinoma
Small cell carcinoma
Large cell carcinoma
Number of bone metastases
The mean age of the patients at the time of the diagnosis of osseous metastasis was 64 years (range 41–88 years). 232 patients (69%) were male and 106 patients (31%) female. Adenocarcinoma was the most frequently diagnosed histological subtype (75%). The performance status was qualified on the basis of the Karnofsky Index. 146 patients (43%) had solitary metastases, while in 192 patients (57%) multiple vertebral bodies were affected.
The osteolytic metastases were rated on a scale from A to G. Subtypes A to C were defined as stable, subtypes D to G as unstable. In cases in which only one lesion was rated as unstable in a patient with multiple metastases, the score was “unstable”. In 74% of the patients (n = 249; 1–12) the thoracic spine was involved, in 26% (n = 89; 1–12) the lumbar spine. 43% of the patients were equipped with an orthopedic thoracic corset.
In 90% of the cases (303 patients) the primary tumor was an NSCLC, in 10% (35 patients) small-cell bronchial carcinoma. 58% of all patients received chemotherapy prior to their radiotherapy; 85% of the patients were under treatment with bisphosphonates.
The most frequent indication for radiotherapy, in 62% of all cases, was pain; further indications were instability (32%), and neurological symptoms (4%). Radiotherapy post- laminectomy surgery was applied in 2%.
Radiotherapy dose completed (Gy)
Single dose (median, range)
Cumulative dose (median, range)
Indication for radiotherapy
Treatment for primary site
Other treatment for bone metastases
Orthopedic thoracic corset
The empirical distribution of continuous variables is described by the number of observations, mean and standard deviation; the description of categorical variables includes the number and percentage of patients belonging to the relevant categories. Bowker’s test and kappa statistics were calculated to detect possible asymmetry in the distribution of the Taneichi score over time. Graphical methods are applied to present the observed data. Multivariable logistic regression analysis was performed to evaluate possible predictors for stability after six months.
981 lesions in 338 patients were assessed according to the Taneichi scoring system  both prior to radiotherapy as well as three and six months post radiotherapy on the basis of CT images. The median follow up of all patients was 9.3 months (mean 12.2, min. 0.4, max. 130.1 month). The survival status at last follow-up showed 26 patients (8%) still alive and 312 patients (92%) death of disease. The most frequent subtype according to Taneichi was subtype C, with 30%. The mean number of metastases per patient was three [1–12]. 64% (215 patients) were classified stable prior to radiotherapy. Of the stable osseous metastases, none were rated unstable in the further course (p < 0.001, McNemar-test). Of the 123 patients in whom the metastases were classified unstable prior to radiotherapy, 21 patients (17%) were classified stable after three months, and 30 patients (24%) stable after six months. This means that in total 70% and 74% of the osseous metastases were stable after three months and six months, respectively (Table 3). Of the prognostic factors for a therapeutic response already described in the literature on several occasions, although the bisphosphonates did not play a significant role regarding stability (p = 0.074, odds ratio (OR) 1.6), they still appear to exert a positive influence (Table 4). The same model was also used for the aspect of fractures; here, however, no particular parameter showed itself to be a prognostic factor. The evaluation of the distribution of subtypes A to G (Table 5) showed a major change in the direction of improvement over the course of time. Deterioration occurred in 1.8% of the cases (n = 6), improvement in 19.3% (n = 63). No change was seen in 78.9% (n = 258) of the cases. In patients with multiple metastases the most negative subtype was rated, postoperative metastases were not considered (n = 11). This test (Bowker test) shows the distribution pattern of the subtypes according to Taneichi prior to and six months after radiotherapy. Asymmetry was apparent (p = 0.0002) and the correlation (kappa = 0.73) was good.
The results of Taneichi Score evaluation
Stability previous RT
Stability after 3 month
Stability after 6 month
Bone fracture before RT
Bone fracture 6 month after RT
Results of prognostic factors related to stability
Chemotherapy (yes vs. no)
Primary site (NSCLC vs SCLC)
Bisphosphonates (yes vs. no)
Number of metastasis (1 vs. > 1)
The evaluation of the distribution of subtypes stable and instable metastases over the course of time (0–6 month)
Subtypes before radiotherapy
Subtypes after 6 month
A pathological fracture was diagnosed in 62 patients (18%) prior to radiotherapy. Regarding cases of osteolytic metastases of the vertebral bodies in which no fracture could be detected prior to the start of therapy, fractures occurred in 2% of the patients (n = 7) within the six months following radiotherapy. Of these 2% (n = 7) six patients were unstable.
An early identification of osseous metastases and their classification in terms of stability is a major factor in the decision for the therapeutical measures to be taken. The scoring system according to Taneichi constitutes a simple method for classifying the vertebral bodies as “stable” or “unstable”, which is why this score is employed in this evaluation.
Osseous metastases in the vertebral bodies are a frequent secondary disease associated with bronchial carcinoma. Palliative percutaneous radiotherapy represents one of the most important measures in this context. Symptoms such as painful mobility impairments, resting pain, fear of pathological fractures, and fatigue result in a substantial reduction in the patients’ quality of life on the one hand; on the other, the treatment of this disease requires protracted therapeutical measures that are highly intensive in terms of cost and time. What is more, some of the patients affected are at an acute risk of fracture, with the potential risk of developing symptoms of paraplegia.
The literature contains various classifications regarding the stability of the vertebral column[9–12]. The essential risk factors for instability comprise an excessive tumor size, the localization of the tumor in the vertebral body, the degree of stress on the vertebral bodies, bone density, the destruction of the costovertebral articulation and of the pedicles in the thoracolumbar spine, and the type of tumor involved. The study by Taneichi et al. defines the risk factors for fractures of the vertebral bodies caused by osteolytic metastases and rates the estimated fractures according to different types of metastatic involvement, establishing criteria for assessing the risk of vertebral-body fractures. The risk factors for vertebral-body fractures in the thoracic region (T1-T10) are the tumor size and the degree of destruction of the costovertebral joint; in the thoracolumbar and lumbar region (T10-L5), it is the tumor size and degree of pedicle destruction that are the main factors.
Our results show that the majority of the patients (64%) already exhibit stable osseous metastases in the vertebral column prior to the start of therapy. Radiotherapy and consecutive resclerotization of the lesions made it possible to reclassify 24% of the originally unstable osteolytic processes as stable after six months. Considering all patients, this means that six months after radiotherapy 72% of the patients can be classified stable. In the literature, the therapeutic response is generally expressed in terms of the quality of pain. The assessment of the therapeutic response using the Taneichi score on the basis of changes in the subtypes has not been described previously. The application of therapeutic measures results in consecutive resclerotization within the osteolytic metastasis, producing an improvement in the Taneichi subtype to the next positive type up on the scale. This change into a better subtype was seen in 19.3% of the lesions. This result represents the therapeutic response of the osteolytic lesions of a bronchial carcinoma following radiotherapy; it is not, however, comparable with the clinical parameters such as pain response.
Bisphosphonates were taken by 85% of the patients, which is why they were not identified as a prognostic factor in terms of stability. Chemotherapy, on the other hand, showed a positive influence in terms of stability and fractures.
The systematic review by Weber et al. defined risk factors regarding spinal instability caused by metastases. Of these risk factors, only the number of metastases showed a positive – albeit insignificant – effect in terms of stability. A uniform classification of spinal metastases in association with bronchial carcinoma has not yet been described in the literature.
In previous retrospective studies among American and Japanese populations, the incidence of pathologic fractures in the vertebral column is given at 10%[1, 15]. There are only few data available regarding the risk of fractures of the vertebral bodies following radiotherapy. Our results show a pathological fracture in 18% of the vertebral bodies prior to radiotherapy. Other fractures up to six months in the further course were seen in 2% of all cases. In a further analysis by Saad et al. the risk of pathological fracture in association with lung cancer is given at 17%; this finding, however, was made relative to the entire skeletal system. Pathological fractures are a frequently encountered event; fractures of the vertebral body following radiotherapy, on the other hand are seldom reported.
The vertebral column as the main axis of the human body stands at the center of all the individual’s mobility faculties; when impaired, it constitutes a mobility-restricting factor. Cheville et al. in their study in patients with an advanced tumor disease showed that radiotherapy can be accompanied by physiotherapy, and that the adjunctive effect of this is beneficial. An active mobilization of these patients has so far been contraindicated according to the recommendations of the German Association for Sports Medicine and Prevention and the German Cancer Society. The strengthening of the paravertebral muscles could be a reasonable therapeutical option for patients with stable osseous lesions, and may produce an improvement in their condition in terms of quality of life, fatigue, and pain. Quality of life is an important factor in palliative-stage patients with bronchial carcinoma, and is substantially impaired by pain, fatigue, and loss of mobility. Seen in this light, the classification of stability prior to the start of therapy is of great importance.
Only few clinics have established a uniform systematic classification in terms of the stability of metastases in the vertebral bodies. The high proportion of stable lesions and the negligibly small proportion of fractures make this a potential new option in the palliative treatment of osseous metastases of the vertebral column. The feasibility of a dedicated sports program for these patients is currently the subject of a prospective study by Rief et al.. Our expectation is that the mobilization of this hithertoin adequately considered category of patients will bring about a considerable improvement in the quality of life of patients with osseous metastases who have undergone radiotherapy. One factor that limited the expressiveness of this analysis, however, is the fact that those patients with a survival time of less than six months and other localizations of osseous metastases were not considered. Usually, the benefit from RT regarding bone recalcification is observed after a minimum of 3–6 months, so patients with a shorter survival will not necessarily benefit from this radiotherapeutic effect, and are thus excluded from analysis.
The use of a systematic radiological scoring system to classify osteolytic metastases of the vertebral column has shown itself to be practicable in the daily routine in the radiology area. The next step that is planned is to use the scoring system for other prospective studies in patients with radiologically treated osseous metastases to validate the physiotherapeutical measures.
Co-authors: Marc Bischof, Thomas Bruckner, Thomas Welzel, Vasileios Askoxylakis, Stefan Rieken, Katja Lindel, Stephanie Combs and Jürgen Debus.
- Tsuya A, Kurata T, Tamura K, Fukuoka M: Skeletal metastases in non-small cell lung cancer: a retrospective study. Lung Cancer 2007, 57: 229-232. 10.1016/j.lungcan.2007.03.013View ArticlePubMedGoogle Scholar
- Coleman RE: Clinical features of metastatic bone disease and risk of skeletal morbidity. ClinCancer Res 2006, 12: 6243-6249.Google Scholar
- Klimo P Jr, Kestle JR, Schmidt MH: Clinical trials and evidence-based medicine for metastatic spine disease. Neurosurg Clin N Am 2004, 15: 549-564. 10.1016/j.nec.2004.04.016View ArticlePubMedGoogle Scholar
- Janjan N, Lutz ST, Bedwinek JM, Hartsell WF, Ng A, Pieters RS Jr, Ratanatharathorn V, Silberstein EB, Taub RJ, Yasko AW, Rettenmaier A: Therapeutic guidelines for the treatment of bone metastasis: a report from the American College of Radiology Appropriateness Criteria Expert Panel on Radiation Oncology. J Palliat Med 2009, 12: 417-426. 10.1089/jpm.2009.9633View ArticlePubMedGoogle Scholar
- Ihde DC: Chemotherapy of lung cancer. N Engl J Med 1992, 327: 1434-1441. 10.1056/NEJM199211123272006View ArticlePubMedGoogle Scholar
- Yu HH, Tsai YY, Hoffe SE: Overview of diagnosis and management of metastatic disease to bone. Cancer Control 2012,19(2):84-91.PubMedGoogle Scholar
- Krebsgesellschaft D: Richtlinien für die Anwendung von Sport und körperlicher Aktivität in der Prävention, supportiver Therapie und Rehabilitation neoplastischer Erkrankungen Teil II. Forum 2011, 5: 9-12.Google Scholar
- Karnofsky DA, Burchenal JH: The Clinical Evaluation of Chemotherapeutic Agents in Cancer. In Evaluation of Chemotherapeutic Agents. Edited by: MacLeod CM. New York: Columbia Univ Press; 1949:191-205.Google Scholar
- Taneichi H, Kaneda K, Takeda N, Abumi K, Satoh S: Risk factors and probability of vertebral body collapse in metastases of the thoracic and lumbar spine. Spine 1997, 22: 239-245. 10.1097/00007632-199702010-00002View ArticlePubMedGoogle Scholar
- Hipp JA, Rosenberg AE, Hayes WC: Mechanical properties of trabecular bone within and adjacent to osseous metastases. J Bone Miner Res 1992, 7: 1165-1171.View ArticlePubMedGoogle Scholar
- Dimar JR, Voor MJ, Zhang YM, Glassman SD: A human cadaver model for determination of pathologic fracture threshold resulting from tumorous destruction of the vertebral body. Spine 1998, 23: 1209-1214. 10.1097/00007632-199806010-00006View ArticlePubMedGoogle Scholar
- Windhagen HJ, Hipp JA, Silva MJ, Lipson SJ, Hayes WC: Predicting failure of thoracic vertebrae with simulated and actual metastatic defects. Clin Othop Relat Res 1997, 344: 313-319.Google Scholar
- Weber MH, Burch S, Buckley J, Schmidt MH, Fehlings MG, Vrionis FD, Fisher CG: Instability and impending instability of the thoracolumbar spine in patients with spinal metastases: a systematic review. Int J Oncol 2011, 38: 5-12.PubMedGoogle Scholar
- Nguyen J, Chow E, Zeng L, Zhang L, Culleton S, Holden L, Mitera G, Tsao M, Barnes E, Danjoux C, Sahgal A: Palliative response and functional interference outcomes using the Brief Pain Inventory for spinal bony metastases treated with conventional radiotherapy. ClinOncol (R CollRadiol) 2011,23(7):485-491.Google Scholar
- Kosteva J, Langer CJ: Incidence and distribution of skeletal metastases in NSCLC in the era of PET. Lung cancer 2004, 46: 45.Google Scholar
- Saad F, Lipton A, Cook R, Chen YM, Smith M, Coleman R: Pathologic fractures correlate with reduced survival in patients with malignant bone disease. Cancer 2007,110(8):1860-1867. 10.1002/cncr.22991View ArticlePubMedGoogle Scholar
- Cheville AL, Girardi J, Clark MM, Rummans TA, Pittelkow T, Brown P, Hanson J, Atherton P, Johnson ME, Sloan JA, Gamble G: Therapeutic exercise during outpatient Radiation therapy for advanced cancer. Am J Phys Med Rehabil 2010, 89: 611-619. 10.1097/PHM.0b013e3181d3e782View ArticlePubMedGoogle Scholar
- Rief H, Jensen AD, Bruckner T, Herfarth K, Debus J: Isometric muscle training of the spine musculature in patients with spinal bony metastases under radiation therapy. BMC Cancer 2011, 11: 482. 10.1186/1471-2407-11-482View ArticlePubMedPubMed CentralGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.